Kornimate/medical-research-clean huggingface dataset:
pediatric resuscitation with feedback cpr devices

Conditions: Cardiac Arrest

Summary: the aim of this study was to compare the truecpr feedback device (with metronome) to standard basic life support (bls) in terms of the quality of single rescuer pediatric resuscitation. therefore, our hypothesis was that there would be no difference between both cpr methods in terms of chest compression quality parameters.

cardiac arrest is a leading cause of death worldwide. high-quality chest compressions are of paramount importance for survival and good neurological outcome. unfortunately, even health professionals have difficulty performing effective cpr. chest compression (cc) is often too shallow, compression ratio is inadequate, and hands-off time is too long. cpr feedback devices might be an option for rescuers to in order to increase cc efficiency.

Eligibility criteria:
inclusion criteria: * give voluntary consent to participate in the study * medical profession (paramedics, nurses, physicians) or medical students (nurses, paramedics, physicians) exclusion criteria: * not meet the above criteria * wrist or low back diseases
visual rehabilitation and depression in visually impaired patients with amd

Conditions: AMD - Age-Related Macular Degeneration; Anxiety; Depression Disorders

Summary: purpose: the aim of this study is to evaluate the impact of visual rehabilitation in visually impaired patients with advanced amd by the use of questionnaires on the anxiety and depression status. study design: prospective observational study. the study is carried out at the irccs fondazione g.b.bietti and at the uo visual rehabilitation, s. alessio - margherita di savoia. study procedures: visit 1 (screening visit, at irccs fondazione bietti) after signing the informed consent, all patients received a complete ophthalmological examination, non-invasive diagnostic tests as optical coherence tomography, autofluorescence and microperimetry, and have to complete the questionnaires on the state of anxiety and depression (gad-7 and phq-9). visit 2 (at the sant'alessio institute) for a 60-day visual rehabilitation program scheduled in 5 group meetings. visit 3 (end-of-study visit, at irccs fondazione g.b. bietti) complete ophthalmological examination, as per clinical practice, non-invasive diagnostic tests such as microperimetry, optical coherence tomography and autofluorescence and administration of the patient health questionnaire-9 (phq-9) questionnaires for depression and the general anxiety disorder (gad-7) questionnaires for anxiety.


Eligibility criteria:
inclusion criteria: 1. subjects ≥ 55 years 2. moderate and severe visual impairment (bcva ≥1/10 and ≤2/10) 3. diagnosis of advanced non-exudative age-related macular degeneration (amd) 4. informed consent freely granted and acquired before the start of the study 5. ability to understand and willingness to follow the study instructions and procedures exclusion criteria: 1. visual impairment due to other ocular diseases 2. mild visual impairment or partial or total blindness 3. exudative age-related macular degeneration undergoing intravitreal drug treatment
iheart-sa intervention study

Conditions: Hypertension; HIV

Summary: using qualitative data during the formative phase the iheart-sa research study filled deficiencies in knowledge regarding: 1) what barriers exist to integrating hypertension care within the hiv care setting in south africa and, 2) how a hypertension care intervention can be adapted to effectively and sustainably function in this care setting. these data have been used to design a context-relevant intervention package for implementation in the next phase of effectiveness-implementation testing, answering the research question: how does an intervention aimed at enhancing hypertension diagnosis and management in people living with hiv improve the delivery of guideline-recommended care in primary healthcare clinics in gauteng, south africa, and hypertension control among patients? the study will use an effectiveness-implementation study design. this design allows for the testing of strategies to promote integration of proven interventions in real-world practice (i.e., implementation strategies), while simultaneously assessing clinical effectiveness (i.e., patient level outcomes). for this the study will use a randomized cluster stepped-wedge study design where nine clinics (grouped in clusters of three) will be assigned to a time at which they initiate the intervention.

investigational interventions: implementation facilitation of improved hypertension screening and management in the hiv care setting through the iheart-sa intervention model comprising: 1. information management system 2. task shifting 3. audit and feedback 4. healthcare worker education and training 5. patient education and support study design: cluster randomized stepped wedge effectiveness-implementation type 2 hybrid study objectives: 1. assess the short- and long-term effects of an implementation strategy (i.e., healthcare worker intervention) on the adoption and implementation of hypertension screening and treatment among healthcare workers 2. assess the short- and long-term effects of a clinical intervention (i.e., patient-level intervention) on patient blood pressure control among patients living with hiv and hypertension duration of participation: 27 months study duration: 37 months intervention audience: 1. healthcare workers (nurses and doctors) 2. adult patients living with hiv from the 9 primary healthcare clinics

Eligibility criteria:
inclusion criteria: healthcare workers: 1. adult \>18 years men and women working in clinical roles at the selected clinics 2. provide informed consent (only those participating in the qualitative components) patients: 1. adults \>18 years living with hiv and hypertension 2. enrolled in the study clinic 3. willing and able to provide informed consent exclusion criteria: patients: 1. unable or unwilling to provide informed consent 2. planning to relocate or change service providers/clinics
does normal brain imaging predict normal neurodevelopmental outcome in fetuses with proven cytomegalovirus infection?

Conditions: CMV; Prenatal Diagnosis; Ultrasound; MRI

Summary: cytomegalovirus (cmv) is the largest member of the virus family herpesviridae that infects almost all humans at some point in their lives (ross, 2004). congenital cmv infection is most likely to occur when the mother experiences a primary infection during pregnancy, and it is much less common in cases of reactivation of the disease or infection by a different cmv strain (boppana 1999, endres 2001). the prevalence of congenital cmv infection varies between 0.15-2.2% (ross 2004, ross 2006, malm 2007). while most infants born with congenital cmv infection are asymptomatic, 10 to 15% show clinical findings at birth (ross 2004). it is generally agreed that congenital cmv infection, whether it is symptomatic or not, is a major risk factor for perceptual deficits. however, its influence on children's future neuropsychological functioning is less well established. symptomatic congenital cmv infection is a major risk factor for poor developmental outcome (williamson 1982, kylat 2006, dollard 2007), but the available data regarding neuropsychological outcome for asymptomatic children is extremely diverse (conboy 1986, ivarson 1997, kashdan 1998, temple 2000, zhang 2007). we evaluated the neuropsychological outcome of children with congenital cytomegalovirus (cmv) infection and normal consecutive fetal neurosonographic examinations and determined whether magnetic resonance imaging (mri) provided additional information in these cases.


Eligibility criteria:
inclusion criteria: * cmv pcr positive in the amniotic fluid exclusion criteria: * us abnormal findings during fetal life

Keywords: cmv prenatal diagnosis ultrasound mri
observational cohort study on the use of parenteral nutrition and clinical outcomes in adult critically ill patients

Conditions: Critical Illness

Summary: the aim of this study is to characterise the use of clinical nutrition support, especially of parenteral nutrition that is administered directly into a vein, in adult patients with critical illness. the study wants to assess nutritional balance (that means the ratio of calories and protein prescribed to calories and protein actually received). furthermore, it wants to evaluate whether the nutrition received has influence on the patients' clinical outcome, with focus on measures of physical function, such as capability of conducting daily living activities. as the study is "observational", no specific medications or treatments will be provided as part of the study to the patients. study patients will be observed during their stay on an intensive care unit, for a maximum duration of 15 days. furthermore, questions on the well-being of the patients will be asked via telephone interviews 30 and 90 days after their admission to the intensive care unit. data of approximately 1250 patients will be collected and evaluated in this study, from approximately 100 hospitals in 11 european countries (austria, belgium, czech republic, france, germany, hungary, italy, poland, spain, sweden and united kingdom).


Eligibility criteria:
inclusion criteria: 1. age ≥18 years and ≤95 years, male or female 2. hospitalised in a medical, surgical, or trauma icu for at least five consecutive calendar days and either admitted to the icu during the predefined screening month or admitted to the icu maximally 4 days before start of the screening month 3. bmi ≥18.5 kg/m2 and ≤45 kg/m2 4. written informed consent or requirements of local/national ethical committee exclusion criteria: 1. burn injury 2. pre-existing neuromuscular or psychiatric disorders that preclude proper assessment of functional status 3. severe hypoxic brain injury or severe neurological diagnosis (e.g. meningitis, encephalitis, brain trauma, spinal cord injury) at the time of icu admission that precludes proper assessment of functional status 4. receiving home parenteral nutrition at the time of icu admission (e.g. due to short bowel syndrome) 5. receiving home enteral nutrition (tube feeding) at the time of icu admission 6. chronic invasive or chronic non-invasive ventilatory support before icu admission 7. patients with a legal representative in place before icu admission 8. admission to the icu for palliative care 9. previous participation in this study (if the screening month is repeated and a patient is re-admitted to the icu during the repeated screening month, only icu data collected for that patient during the original screening month will be included) 10. concurrent enrolment in a nutrition-related interventional study at the time of screening

Keywords: icu parenteral nutrition enteral nutrition energy intake protein intake
treatment of early onset schizophrenia spectrum disorders (teoss)

Conditions: Schizophrenia

Summary: this study will evaluate the safety and efficacy of risperidone (risperdal®), olanzapine (zyprexa®), and molindone (moban®) for the treatment of children and adolescents with schizophrenia or schizoaffective disorder.

little research has been conducted on the use of psychotropic agents in children and adolescents with early onset schizophrenia spectrum disorders. this study will compare antipsychotic agents with different mechanisms of action in children and adolescents who have schizophrenia or schizoaffective disorder with active psychotic symptoms. participants are randomly assigned to receive risperidone (risperdal), olanzapine (zyprexa), or molindone (moban) for 8 weeks. after 11/2005, no additional patients will be assigned to olanzapine treatment. patients with significant improvement and without side effects continue maintenance therapy for another 44 weeks. participants who show significant negative symptoms after 8 weeks may be started on a mood stabilizer or antidepressant. weight gain, metabolic changes, neurocognition, functional outcome, psychotic symptoms, extrapyramidal side effects, and the ability to sustain effective therapy over time are assessed.

Eligibility criteria:
inclusion criteria: * schizophrenia, schizophreniform disorder, or schizoaffective disorder with psychotic symptoms * free of depot antipsychotic medication for at least 6 months. oral antipsychotic medication at entry into the study is allowed, provided the participant has not had an adequate trial during the present episode of psychosis. * if taking antidepressant or mood stabilizing medication, stable dosing for at least 30 days prior to entry. * good physical health exclusion criteria: * risperidone (ris), olanzapine (ola)\*, or molindone (mol) for 8 weeks or more during this episode, with 2 weeks at the maximal dose (6 mg/day of ris, 20 mg/day of ola, or 140 mg/day of mol) * if using antidepressant and/or mood stabilizing medications, treatment for fewer than 30 days immediately before entry * intolerance or nonresponse to ris, ola\*, or mol during any previous treatment * bipolar affective disorder,post traumatic stress disorder, personality disorder, or psychosis not otherwise specified * currently meeting diagnostic and statistical manual version iv (dsm iv) criteria for major depression episode * dsm iv criteria for substance abuse or dependence with intention to continue illicit substance abuse * endocrinological or neurological conditions which confound the diagnosis or are a contraindication to treatment with antipsychotics * mental retardation * risk of suicide or homicide that is not adequately controlled in the current setting * pregnancy or refusal to practice contraception during the study "\*" ola exclusion not applicable after 11/2005

Keywords: psychotic disorders schizophreniform disorder
french colorectal esd cohort in experts centers

Conditions: Cancer Colorectal; Polyps Colorectal; Endoscopic Submucosal Resection

Summary: initially developed in japan for the treatment of endemic superficial gastric cancers, endoscopic submucosal dissection (esd) allows resection of pre-neoplastic and neoplastic lesions of the digestive tract into a single fragment. it allows a perfect pathological analysis, and decreases the rate of recurrence of the adenoma to less than 2%. however, this procedure, which is technically more challenging, is also more risky (perforation rate at 4% vs. 1% for wf-emr) and longer. submucosal dissection is also more expensive in terms of equipment, but this difference can be offset by the cost of the high number of iterative colonoscopies required in patients who have had endoscopic resection by wf-emr. scientific debate is agitating the western world1,2 and japanese experts do not perform wf-emr anymore, whereas no comparative prospective study has compared these two procedures. a lot of centers in france performed colorectal esd even for benign lesions and nationwide data about safety and efficiency is required to confirm the place of esd for treatment of large superficial colorectal lesions.

initially developed in japan for the treatment of endemic superficial gastric cancers, endoscopic submucosal dissection (esd) allows resection of pre-neoplastic and neoplastic lesions of the digestive tract into a single fragment. it allows a perfect pathological analysis, and decreases the rate of recurrence of the adenoma to less than 2%. however, this procedure, which is technically more challenging, is also more risky (perforation rate at 4% vs. 1% for wf-emr) and longer. submucosal dissection is also more expensive in terms of equipment, but this difference can be offset by the cost of the high number of iterative colonoscopies required in patients who have had endoscopic resection by wf-emr. scientific debate is agitating the western world1,2 and japanese experts do not perform wf-emr anymore, whereas no comparative prospective study has compared these two procedures. a lot of centers in france performed colorectal esd even for benign lesions and nationwide data about safety and efficiency is required to confirm the place of esd for treatment of large superficial colorectal lesions.

Eligibility criteria:
inclusion criteria: all patients addressed for a colorectal esd exclusion criteria: opposition notified in the context of a non-opposition form after reading the information notice

Keywords: cancer colorectal polyps colorectal endoscopic submucosal resection
multicentre observational study on community acquired intraabdominal infections management

Conditions: Intraabdominal Infections

Summary: intraabdominal infection require rapid care management including antibiotic therapy and source control. morbidity and mortality associated with intraabdominal infections remain high. french recommendations have been edited in 2000 further updated in 2014. delay in diagnosis and surgery can lead to worsened outcomes. however, little data are available on early community-acquired intraabdominal infections management to identify risk factors of inadequate management.


Eligibility criteria:
inclusion criteria: * ≥ 18 years * patients admitted to emergency department for a diagnosis of proven or suspected intraabdominal infection requiring surgery exclusion criteria: * primary intraabdominal infection * health-care associated intraabdominal infection * abdominal trauma * patient under guardianship * opt out consent * patient already enrolled in the present study

Keywords: intraabdominal infections peritonitis critically ill
evaluation of hemodynamics and amount of blood flowing through the kidneys by measuring some physiological substances in blood and urines

Conditions: Hypovolemia; Renal Hypoperfusion

Summary: the purpose of this study is to verify any existing relationship between mixed oxygen saturation (from central venous catheter) and urinary sodium, potassium, chloride in determining the volemic state and renal perfusion of patients undergoing major surgical interventions.


Eligibility criteria:
inclusion criteria: * thoracic-abdominal major surgical operations * placing of a central venous catheter and urinary catheter * age 18-75 * asa class i-iii exclusion criteria: * age above 75 or under 18 * asa class iv * trauma, sepsis and/or heart-lung failure * liver transplantation * kidney transplantation * pre-existing renal failure * pregnant patients * patients unable to give their written consent

Keywords: hypovolemia renal hypoperfusion major surgery sodium potassium chloride scvo2 hemodynamic indexes
reliability and responsiveness of the chinese version of the readiness for return-to-work scale in lost-time claimants in outpatient occupational rehabilitation in taiwan

Conditions: Occupational Injuries

Summary: the aim of the study is to measure the reliability and responsiveness of the chinese version of the readiness for return-to-work (rrtw) scale. we would conduct a multiple-centered, prospective cohort study to require rrtw data in lost-time claimants in outpatient occupational rehabilitation in taiwan.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of occupational injuries * participating the work hardening program * age from 20-65 * still not return to work * willing to participating the study exclusion criteria: * cannot read the sentences or express their own idea, which causing the cannot finish the questionnaires * brain injuries (e.g. traumatic brain injury, cerebrovascular acciden

Keywords: return to work readiness for return to work occupational injury work hardening
upfront immune checkpoint inhibitors with deferred cytoreductive nephrectomy for metastatic renal cell carcinoma

Conditions: Clear-cell Metastatic Renal Cell Carcinoma; Immune Checkpoint Inhibitors; Cytoreductive Nephrectomy

Summary: study objective: to determine the efficacy of upfront immune checkpoint inhibitors combined with deferred cytoreductive nephrectomy in treating metastatic renal cell carcinoma. primary endpoint: pathological major response (mpr), defined as the percentage of residual tumor cells \<10% in the primary tumor after nephrectomy. study design: population: participants meeting the diagnostic criteria with biopsy-proven clear cell renal cell carcinoma, imdc score ≤3, or ≤5 metastatic lesions involving ≤3 organs. sample size: 20 participants. patient grouping: non-randomized. interventions: eligible participants will receive upfront treatment with a combination of axitinib and toripalimab for 4 cycles. after 2 cycles of treatment, radiological assessment will be conducted using recist 1.1 criteria. if disease progression is observed, the clinical trial will be terminated, and second-line treatment will be initiated according to guidelines. if disease progression is not observed, treatment will continue for 2 additional cycles followed by repeat radiological assessment before undergoing surgery.


Eligibility criteria:
inclusion criteria: voluntary consent to participate in this study and signing of an informed consent form. male or female participants aged ≥18 years and \<80 years. histologically diagnosed with clear cell carcinoma or predominantly clear cell renal cell carcinoma. clinical stage determined by ct or mri: anytn1m0 or anytn0m1; imdc score ≤3, or ≤5 metastatic lesions involving ≤3 organs; and the primary tumor (unilateral or bilateral) is resectable. ecog performance status: 0 or 1. no clinically significant cardiac, bone marrow, hepatic, or renal function abnormalities. a willingness and ability to comply with testing and follow-up procedures. exclusion criteria: non-clear cell carcinoma. severe liver or kidney dysfunction, or other severe diseases. immune deficiency, organ transplantation, or autoimmune diseases. severe central nervous system diseases. other malignant tumors within the past 5 years, except for cured basal cell carcinoma of the skin and cervical carcinoma in situ. unable to comply with regular follow-up visits due to psychological, social, family, or geographical reasons.
positron emission tomography (pet) study to describe the relationship between plasma concentrations and brain gly-t1 occupancy of gsk1018921 over time.

Conditions: Schizophrenia

Summary: a pet study using \[11c\]gsk931145 to characterise the exposure-occupancy relationship over time for gsk1018921.

this is an open-label, adaptive-design, single-dose, non randomized pet occupancy study.the primary aim of this study is to describe the relationship between plasma concentrations and brain occupancy of gsk1018921 over time. up to 22 healthy volunteers will be administered single doses of gsk1018921 in order to obtain 12 evaluable complete data sets of occupancy estimates.

Eligibility criteria:
* inclusion criteria: * healthy male subjects * age: 18-55 years * no history of physical, neurological or mental illness * exclusion criteria * history of claustrophobia or inability to lie still in the pet camera for at least 2 hours * cardiac pacemakers or metal implants in the body that contraindicate mri scan. * history of regular alcohol consumption (weekly intake \>21 units) within the previous six months.

Keywords: glycine tranporter mri pet